Glycotope to present platform approach for development of anti-GlycoTarget antibodies at 2024 AACR Meeting
08. April 2024 02:00 ET
|
Glycotope
Glycotope to present platform approach for development of anti-GlycoTarget antibodies at 2024 AACR Meeting Berlin, Germany, 08 April, 2024 – Glycotope GmbH, a biotechnology company utilizing a...
Glycotope Presents anti-GlycoTarget Antibodies at the 2023 Society for Immunotherapy of Cancer (SITC) Meeting
03. November 2023 03:58 ET
|
Glycotope
Glycotope Presents anti-GlycoTarget Antibodies at the 2023 Society for Immunotherapy of Cancer (SITC) Meeting Berlin, Germany, 03 November, 2023 – Glycotope GmbH, a biotechnology company with a...
Therabest and Glycotope to assess Therabest’s iPSC-derived NK cell product TB-100 in combination with Glycotope’s GT-00AxIL15 immuno-cytokine for development in triple negative breast cancer
13. Dezember 2022 02:00 ET
|
Glycotope
Therabest and Glycotope to assess Therabest’s iPSC-derived NK cell product TB-100 in combination with Glycotope’s GT-00AxIL15 immuno-cytokine for development in triple negative breast cancer San...
Glycotope Presents GlycoTarget Platform and New Data on Platform-Derived anti-LYPD3 Antibody at 2022 Society for Immunotherapy of Cancer (SITC) Meeting
08. November 2022 02:00 ET
|
Glycotope
Glycotope Presents GlycoTarget Platform and New Data on Platform-Derived anti-LYPD3 Antibody at 2022 Society for Immunotherapy of Cancer (SITC) Meeting Berlin, Germany, 08 November, 2022 –...
Glycotope Announces New Strategy to Maximize Potential of Uniquely-Tumor Specific Antibody Platform
24. März 2022 03:00 ET
|
Glycotope
Glycotope Announces New Strategy to Maximize Potential of Uniquely-Tumor Specific Antibody Platform Expansion of senior team to focus on drug discovery and developmentPlatform combines glycobiology...
Glycotope Presents New Data on Carbohydrate-Dependent Antibodies and Fusion-Proteins at the 2021 Society for Immunotherapy of Cancer (SITC) Meeting
15. November 2021 03:00 ET
|
Glycotope
Glycotope Presents New Data on Carbohydrate-Dependent Antibodies and Fusion-Proteins at the 2021 Society for Immunotherapy of Cancer (SITC) Meeting Glycotope Poster Presentation at the 2021 Society...
DCprime and Glycotope Sign Licensing Agreement to Advance Program Combining Cancer Vaccination and Therapeutic Antibody Platforms
21. September 2020 04:00 ET
|
Glycotope
DCprime and Glycotope Sign Licensing Agreement to Advance Program Combining Cancer Vaccination and Therapeutic Antibody Platforms Leiden, The Netherlands, and Berlin, Germany, September 21, 2020 -...
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
30. Juli 2018 03:00 ET
|
Glycotope
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate Tokyo, Berlin, Basking Ridge, NJ – (July 30, 2018) – Daiichi Sankyo Company, Limited...